NASDAQ:PRPO

PRECIPIO
EXPECT MORE.

COMPANY OVERVIEW

Precipio, Inc. (NASDAQ: PRPO) is a healthcare biotechnology company focused on cancer diagnostics, founded in 2011 and headquartered in New Haven, Connecticut. Their mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Their products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in the laboratory where they design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio's reach to eradicate misdiagnosis.

Precipio runs two divisions inside one company. The Pathology Services Division delivers specialized cancer diagnostic testing to oncology practices, hospitals, and reference laboratories from two CLIA-certified laboratories in New Haven, Connecticut and Omaha, Nebraska. The Products Division develops and commercializes proprietary diagnostic assays for use by other clinical laboratories.

The two divisions are built to feed each other. The clinical laboratory generates recurring service revenue, supplies the patient samples and infrastructure that research depends on, and serves as the first validation environment for every new product. Precipio's product platforms, BloodHound, HemeScreen and IV-Cell, were developed and refined against real cases inside that laboratory before commercial release. It is a structure the company regards as a competitive advantage. Precipio cites studies indicating that blood-cancer diagnoses may be misclassified in approximately one-quarter of cases, and separately cites an estimate that diagnostic error across the U.S. healthcare system costs approximately $100 billion annually.

KEY CONSIDERATIONS

- TWO DIVISIONS THAT FEED EACH OTHER. THE CLINICAL LAB EARNS RECURRING REVENUE AND DOUBLES AS THE DEVELOPMENT AND VALIDATION ENVIRONMENT FOR THE PRODUCTS BUSINESS.
- A DOCUMENTED DIAGNOSTIC PROBLEM. PRECIPIO CITES STUDIES INDICATING BLOOD-CANCER DIAGNOSES MAY BE MISCLASSIFIED IN ROUGHLY ONE IN FOUR CASES.
- PRODUCTS DESIGNED TO RUN ON WIDELY USED PCR EQUIPMENT. BLOODHOUND & HEMESCREEN PANELS USE STANDARD RT-PCR MACHINES, ROUGHLY $30,000 TO $75,000, VERSUS PLATFORMS THAT CAN EXCEED $1 MILLION.
- IV-CELL CELL CULTURING MEDIA REMOVES AN UPFRONT GUESS, DESIGNED TO FUNCTION UNIVERSALLY ON ALL BLOOD CELLS. CONVENTIONAL MEDIA FORCE A LAB TO PICK ONE OF FOUR CELL LINEAGES UP FRONT, WRONG IN ABOUT 40% OF CASES; IV-CELL CULTURES ALL FOUR AT ONCE.
- REVENUE GROWTH AND POSITIVE CASH FLOW. NET SALES REACHED ABOUT $24.0 MILLION IN 2025, UP ROUGHLY 30%, AT A 45% GROSS MARGIN, WITH POSITIVE OPERATING CASH FLOW.
- PRODUCTS CARRY THE HIGHER MARGIN. PRODUCTS RAN ABOUT A 54% GROSS MARGIN IN 2025 VERSUS 43% FOR SERVICES, ON ROUGHLY 11% OF REVENUE, AND GROWING IT IS A PRIORITY, WITH A POTENTIAL OF BEING MUCH HIGHER AT SCALE.

DIAGNOSTICS BUILT INSIDE A WORKING LABORATORY.

Precipio develops its products against real patient cases in its own CLIA-certified labs, then sells them to the laboratories facing the same problems.

A LAB THAT DOUBLES AS R&D

BloodHound, HemeScreen and IV-Cell were all developed and validated inside Precipio's own clinical laboratory before commercial release.

WIDELY USED RT-PCR EQUIPMENT

BloodHound & HemeScreen panels run on standard RT-PCR machines already widely used in clinical laboratories, avoiding capital outlays that can exceed $1 million.

FOUR LINEAGES, CULTURED AT ONCE

IV-Cell allows simultaneous culture of all four hematopoietic cell lineages, removing a guess that goes wrong in roughly 40% of cases.

PANELS BUILT TO THE GUIDELINES

BloodHound & HemeScreen panels typically target four to seven genes or clinically relevant variants selected for a specific disease workup.

TWO WEEKS DOWN TO TWO DAYS

Precipio reports that customers using HemeScreen have reduced molecular-test turnaround from approximately two weeks to two days.

REACH THROUGH PARTNER NETWORK

Channel partner agreements carry the products to physician-owned laboratories, hospitals, academic centers, and reference laboratories.

FIXING A DIAGNOSTIC BOTTLENECK FROM INSIDE THE LABORATORY

Blood cancers are diagnosed through molecular and cytogenetic testing, and the studies Precipio cites suggest those diagnoses are misclassified in roughly one in four cases. Separately, the company cites an estimate that diagnostic error across U.S. healthcare costs nearly $100 billion annually.

Founded in 2011 in New Haven, Connecticut, Precipio built its answer around one structure: a clinical laboratory that serves patients while also developing the diagnostic products it sells to other laboratories. Each product is developed and refined using real patient samples before release, so the two businesses reinforce each other.

The larger products are BloodHound & HemeScreen, a family of molecular panels covering myeloproliferative neoplasms, AML, CLL, cytopenia, and BCR-ABL, typically built around four to seven genes or clinically relevant variants selected for disease-specific workups under NCCN and WHO guidelines. Its advantage is the instrument: RT-PCR machines already widely used in clinical laboratories, roughly $30,000 to $75,000, rather than platforms that can exceed $1 million. Labs using the panels have cut molecular turnaround from about two weeks to two days, and the 2024 BloodHound BCR-ABL1 and MPN assays added automated quantitative results at lower detection limits.

IV-Cell addresses a different bottleneck. Cytogenetic testing requires culturing cells first, and conventional media force the lab to commit to one of four cell lineages at the outset, a choice made on the ordering oncologist's suspicion that Precipio's data show is wrong in about 40% of cases, where it can yield a false negative. IV-Cell is designed to function universally on all blood cell lineages, removing the upfront choice, validated on more than 1,000 clinical specimens.

Those products anchor a growing commercial business. Net sales reached about $24.0 million in 2025, up roughly 30% at a 45% gross margin, with positive operating cash flow in the fourth quarter and for the year. Pathology services provide the volume while the higher-margin products business, near 54% against 43% on about 11% of revenue, is where management is concentrating growth. National channel partners carry the line to clinical laboratories nationwide, in a blood-cancer genetics market Precipio sizes near $500 million, within far larger cancer-genetics and molecular-diagnostics markets.

~$24.0M
FY2025 Net Sales

~30%
FY2025 Revenue Growth

20+
States Served

~$500M
Estimated Blood-Cancer Genetics Market Size

LEADERSHIP

ILAN DANIELI
CO-FOUNDER & CHIEF EXECUTIVE OFFICER

- LEADS PRECIPIO'S INTEGRATED PATHOLOGY-AND-PRODUCTS OPERATING MODEL
- RESPONSIBLE FOR COMMERCIAL, OPERATIONAL, AND CAPITAL STRATEGY
- REPRESENTS THE COMPANY IN QUARTERLY SHAREHOLDER CALLS AND INVESTOR COMMUNICATIONS

ZAKI SABET
CO-FOUNDER & CHIEF OPERATING OFFICER

- OVERSEES OPERATIONAL EXECUTION ACROSS THE COMPANY'S LABORATORY AND PRODUCTS BUSINESSES
- RESPONSIBLE FOR THE CLIA-CERTIFIED FACILITIES IN NEW HAVEN, CONNECTICUT AND OMAHA, NEBRASKA
- HOLDS MANUFACTURING OVERSIGHT FOR THE PRODUCTS DIVISION



AYMAN MOHAMED, M.D.
CO-FOUNDER & CHIEF TECHNOLOGY OFFICER

- LEADS TECHNOLOGY DEVELOPMENT AND ASSAY ENGINEERING
- OVERSEES THE BLOODHOUND, HEMESCREEN & IV-CELL PLATFORMS
- DIRECTED THE INVENTION AND DEVELOPMENT OF PRECIPIO'S DIAGNOSTIC TECHNOLOGIES

MATT GAGE
CHIEF FINANCIAL OFFICER

- OVERSEES FINANCIAL REPORTING, PLANNING AND CAPITAL-MANAGEMENT ACTIVITIES
- PROVIDES FINANCIAL AND OPERATING-PERFORMANCE CONTEXT IN INVESTOR COMMUNICATIONS
- SUPPORTS THE COMPANY'S QUARTERLY RESULTS DISCLOSURES



MIRI CHIKO-RADOMSKI
CHIEF LEGAL COUNSEL AND PEOPLE OFFICER

- ADVISES ON EQUITY CAPITAL MARKETS, CORPORATE GOVERNANCE, SECURITIES AND COMPANY LAW, AND M&A TRANSACTIONS
- BRINGS INTERNATIONAL LEGAL EXPERIENCE SPANNING SWEDEN, ENGLAND, AND ISRAEL, AND HOLDS AN L.L.M FROM KING'S COLLEGE LONDON